Therapeutic Targets Database
BIDD Pharmainformatics Databases


TTD Drug ID: DAP001119

Drug Information
SynonymsBSPBio_000799; NCGC00178860-03; 10-[2-(Diethylamino)-1-Propyl]phenothiazine; C19H24N2S; 10H-Phenothiazine-10-ethanamine, N,N-diethyl-.alpha.-methyl-; KBioGR_001215; Phenoprozine; Profenamina [INN-Spanish]; Parcidol; Athapropazine; Athopropazin; Spectrum4_000548; Spectrum3_000429; N,N-diethyl-1-phenothiazin-10-ylpropan-2-amine; CID3290; 522-00-9; Isothiazine; Fempropazine; Fenpropazina; Prestwick0_000840; Prodierazine; Profenamina; Spectrum_000815; PHENOTHIAZINE, 10-(2-(DIETHYLAMINO)PROPYL)-; CHEMBL1206; Parsotil; Aethopropropazin; nchembio.154-comp13; Profenamine (INN); NCIOpen2_008174; Parkin; Profenamina [Italian]; Prestwick3_000840; Rodipal; Prestwick2_000840; Profenaminum [INN-Latin]; Prestwick1_000840; BPBio1_000879; N,N-Diethyl-alpha-methyl-10H-phenothiazine-10-ethanamine; Prodictazin; IDI1_000061; Parsidol; Rocipel; Spectrum5_001592; D08426; AB00053474; ethopropazine; Phenopropazine; Etopropezina; Profenamine [INN:BAN]; KBio2_001295; EINECS 208-320-4; Parsidan; 10-[2-(Diethylamino)propyl]phenothiazine; SPBio_002720; DB00392; KBioSS_001295; Prophenamine; KBio3_001238; 10-[2-(Diethylamino)-2-methylethyl]phenothiazine; NINDS_000061; Isopthazine; Prophenaminum; BSPBio_002018; KBio1_000061; Rochipel; Lysivane; Isothazine; Ethapropazine; Parfezine; Pardidol; 2-Diethylamino-1-propyl-N-dibenzoparathiazine; DivK1c_000061; 10-(2-Diethylaminopropyl)phenothiazine; SKF 2538; SC 2538; CHEBI:313639; Parkisol; Spectrum2_000984; 10H-Phenothiazine-10-ethanamine, N,N-diethyl-alpha-methyl-; Ethopromazine; KBio2_003863; W 483; UNII-7WI4P02YN1; KBio2_006431; AC1L1FLK; N,N-Diethyl-1-(10H-phenothiazin-10-yl)-2-propanamine; L001334; SPBio_001047; Isotazin; LS-105451; Parsitan; Profenaminum; N,N-diethyl-1-(10H-phenothiazin-10-yl)propan-2-amine; Profenamine; RP 3356    
Trade NameParsidol; Parsidan; Parkin    
IndicationParkinson's diseaseApproved    [1]

Click to save drug structure in 3D MOL format

Click to save drug structure in 2D MOL format
Therapeutic ClassAntiparkinson Agents    
CAS NumberCAS 1094-08-2
PubChem Compound IDCID 3290.    
PubChem Substance IDSID 153942.    
SuperDrug ATC IDN04AA05;    
SuperDrug CAS ID000522009;    
TargetMuscarinic acetylcholine receptor M1Antagonist[2]
Ref 1Drugs used to treat Parkinson's disease, present status and future directions. CNS Neurol Disord Drug Targets. 2008 Oct;7(4):321-42. To Reference
Ref 2The relative selectivity of anticholinergic drugs for the M1 and M2 muscarinic receptor subtypes. Mov Disord. 1986;1(2):135-44. To Reference


Welcome to sign our Guestbook.

If you find any error in data or bug in web service, please kindly report it to Dr. Zhu.

Dr. Chen Yuzong
Deputy Director of Center for Computational Science and Engineering
Professor in Department of Pharmacy
National University of Singapore, Singapore

All rights reserved.

Computer-aided Drug Design
About BIDD | Databases | Software | Teaching | Research |  Links

Department of Computational Science | National University of Singapore | Blk S17, 3 Science Drive 2, Singapore 117543